THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, December 26, 2023
Integrated data flow between devices and people, remote monitoring, and real-time analytics can make medical ecosystems more efficient.
FREMONT, CA: Pharmaceutical companies are on the cusp of an Internet of Things (IoT) revolution that could revolutionize patient care, unleash new business models, and revolutionize the patient experience. The method has participated in several IoT initiatives aimed at patients with complex health conditions. IoT initiatives fail because companies need a coherent strategic direction. They overestimate the ability of technology to address a patient problem and, worst of all, lose sight of the end-user.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
One of the most significant obstacles in designing patient-centric solutions for pharma manufacturers is that they are frequently one step removed from the patient experience, interacting with patients through hospitals, physicians, reps, and pharma retailers. For IoT projects to be successful, pharma brands must get much closer to patients and develop an in-depth comprehension of their daily lives and empathy for the difficulties associated with living with their particular health conditions. How patients interact with their healthcare system and acquire their medications can vary based on age, location, and financial resources.
Successful Internet of Things devices, regardless of industry, address a human problem or fulfill a human need. There is no substitute for design and innovation teams immersing themselves in the real world and online communities of patients to gain firsthand insight into the patient experience and potential solutions. By immersing themselves in the patient experience, pharma companies will better understand their patients' challenges, what needs to be enhanced, and how service delivery affects patient engagement levels.
Biopharma leaders want greater clinical trial decentralization, platforms for innovative medicines, digitalization, real-world data and evidence, outsourcing, and patient diversity. Private and governmental financing and deal prices will slow in 2023. Beyond COVID-19, Biopharma businesses will increase mRNA-based medication and vaccine development. For instance, IoT assists patients with cognitive disorders like Alzheimer's in remembering to take their medication or attend doctor's appointments.
As long as it is founded on rigorously derived insights, IoT design has the potential to fundamentally transform patients' interactions with their medication and with their healthcare providers. The private sector and the research community are investigating the role of smart contact lenses in healthcare, such as for glaucoma diagnosis and assisting people with diabetes in monitoring their blood glucose levels. With trending topics such as IoT, it is essential to avoid confirmation bias – the unverified belief that IoT is the best or only solution to a business problem.
Pharmaceutical companies must focus on the technology's capabilities rather than the patient's requirements. It may subsequently result in setbacks, higher-than-expected costs, or squandered opportunities. Part of making IoT work is ensuring it can uniquely solve or contribute to the problem while remaining open to superior alternatives. While patient needs should drive IoT pharmaceutical innovation, solutions must also deliver the anticipated return on investment (ROI).
Comprehending the market is equally as crucial as understanding the patient. It entails analyzing alternative solutions, evaluating future-oriented trends and legislation, and researching how purchasing functions in various markets. Developing, visualizing, and testing business models against actual market conditions is essential. Diabetes is one area in which a comprehensive IoT ecosystem has developed that addresses a genuine consumer need and represents a suite of commercially viable products and services.
More in News